INTRODUCTION
We focused on major venous occlusions and duodenal lesions in the rat and treatment with the stable gastric pentadecapeptide BPC 157, which is a prototype cytoprotective agent used in ulcerative colitis and multiple sclerosis trials (LD1 not achieved) and is known to counteract duodenal lesions [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Rat duodenal lesion research is mostly based on cysteamine and acetic acid models [11] [12] [13] [14] ; investigations are sparse on the impact of major venous obstruction and whether recruitment of blood vessels to bypass obstruction may occur quickly, and if so, whether it may be facilitated by a suitable therapy. On the other hand, in rats that underwent other vessel occlusions (i.e., left colic artery and vein, infrarenal inferior caval vein [15, 16] ), after application of stable gastric pentadecapeptide BPC 157, the bypassing occurs through a rapid collateral presentation, and the lesions and consequent syndrome were largely attenuated. Rapidly reestablished arcade vessel interconnections upon BPC 157 application mitigated the harm in two ligations of the left colic artery and vein and consequently alleviated ischemic colitis as well [15] . In rats with infrarenal inferior caval vein occlusion, the therapeutic effect occurs through the immediate presentation of the left ovaric vein (LOV) and other veins, bypassing the obstruction, and counteracting all the symptoms of Virchow's triad [16] . The normalized levels of two oxidative stress markers, nitric oxide (NO) and malondialdehyde (MDA), in tissues as well as the reduced L-NAME and L-arginine effects showed BPC 157 effectiveness over the NO-system background [15, 16] . These findings were related [15, 16] to the cytoprotective agents, to the effects originally noted in the stomach, which is the rapid endothelial protection. Using BPC 157 as a prototype cytoprotective agent [15, 16] , these mechanisms can prevent and resolve adjacent ischemic mucosal lesions [17] [18] [19] [20] [21] providing activation of the collateral circulation [15, 16] . This activation is specific and can circumvent obstructions [15, 16] . That factor had not been considered in vascular studies of ischemic colitis or deep vein thrombosis [22] [23] [24] [25] . As a result exerted within the immediate post-injury time in vascular studies of ischemic colitis or deep vein thrombosis [15, 16] , it reestablishes the continuity of blood flow, in particular [15, 16] . Also, this effect was shown to be a long-lasting effect [15, 16] . It was also applicable in the later period, even after additional colon or major vein obstruction had occurred [15, 16] . This will also resolve mucosal lesions that would appear with disturbed duodenal circulation, if the cytoprotection/endothelium protection is essential [15, 16] to quickly restore blood supply to the ischemic area, and if the application of BPC 157 may offer a fundamental treatment with the rapid and successful recruitment of blood vessels during harmful events. In support, various harmful conditions, all overwhelmed, such as vascular obstruction, short-lasting blood deprivation, reperfusion, long-lasting blood deprivation and additional bowel obstruction, verify that BCP 157 can rapidly activate collaterals as we suggested [15, 16] . We treated occluded superior anterior pancreaticoduodenal veins (SPDAVs) and duodenal lesions (that would otherwise rapidly appear and sustainably progress) with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine. Namely, interaction between BPC 157 and NO-system goes in different systems and species. This was also demonstrated using both L-NAME and L-arginine as individual agents or in combination [1] [2] [3] [4] [5] in cytoprotection studies. Furthermore, venous obstruction may be more damaging to the intestine than corresponding artery occlusions and rapidly induces mucosal lesions (i.e., within 5 min in the case of the superior mesenteric vein) [26] . Thus, bypassing one or more of the vascular obstructions and thereby achieving a therapeutic effect [15, 16] appears, if BPC 157 rapidly activates collaterals due to its particular direct and rapid effect on vessel presentation. The main focus of the intervention was parallel with the findings in the colon and venous tissues [15, 16] . Levels of oxidative stress MDA and NO were also assessed in duodenal tissue, and the results showed NO-and MDA-duodenal tissue levels and relative to the ligation course or therapeutic effects.
MATERIALS AND METHODS

Animals
We used male Albino Wistar rats, 200 g b.w., randomly assigned to groups with at least 7 rats per group. Local ethics committee approved all of the experiments. Rats had access to food and water ad libitum before the procedure and until the end of the experiment. The surgical procedure was performed as well as the assessments were performed by a blinded observer.
Drugs
We used the pentadecapeptide Gly-Glu-Pro-Pro-ProGly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, M.W. 1419, named BPC 157 (Diagen, Ljubljana, Slovenia), freely soluble in water at pH 7.0 and in saline, prepared as previously described [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . L-NAME (Sigma, United States) and L-arginine (Sigma, United States) were used as previously described [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] .
Experimental procedure and assessment
Surgery:
The surgery was conducted in deeply anesthetized rats. The SAPDV was occluded by ligation (Premilene 7/0, Braun) of 5 arcade vessels at the duodenal serosa within the SAPDV branches. The 30-mm blood-flow affecting a duodenum segment was marked ( Figure 1 ).
Medication:
We used two regimens of BPC 157 application: 10 μg, 10 ng/kg per 1 mL bath/rat or 10 μg/kg instilled into the rat stomach, at 1 min ligationtime. To investigate the effect of NO-agents [L-NAME (NO-system-blockade), L-arginine (NO-system over-stimulation); L-NAME+L-arginine (NO-system immobilization)] we used L-NAME 5 mg/kg per 1 mL bath/rat; L-arginine 100 mg/kg per 1 mL bath/rat, alone and/or together. Controls received a saline bath of equal volume at 1 min of ligation time or an equal volume of saline instilled into the stomach of the SAPDV-ligated rats.
Assessment: Considering the point immediately before therapy (as 100%) [see the assessment shown in Figure 1 (SAPDV rats)], we scored the vessel presentation {recorded filled/appearance or emptied/ disappearance [camera attached to a USB microscope (Veho discovery VMS-004 deluxe)]} between the 5 arcade vessels arising from the SAPDV on the ventral duodenum side (as described before [15] ), the IAPDV, SMV as bypassing vascular pathway. Scoring 0-3 was as follows: 0, presentation similar to healthy rats; 1, mild congestion; 2, moderate congestion; and 3, severe congestion, after 5 min; then, at 30 min, at 24 h. Likewise, upon the duodenum opening and after h ligation time, we determined the NO levels (μmol/mg protein) in the duodenum tissue samples using the Griess reaction (Griess Reagent System, Promega, United States). Briefly, we added sulfanilamide to the homogenized tissue; we incubated the mixture, and added N-1-naphthylethylenediamine dihydrochloride. We measured absorbance at 540 nm using a sodium nitrite solution as a standard. We determined protein concentrations using a commercial kit (BioRad Protein DR Assay Reagent Kit, United States).
Statistical analysis
We used parametric one-way ANOVA with a post hoc Newman-Keuls test, nonparametric Kruskal-Wallis and subsequent Mann-Whitney U-test to compare the groups. We considered P < 0.05 to be statistically relevant.
RESULTS
The regular perilous course in rats with SAPDV occlusion
Failure progressed in control SAPDV-ligated rats (5-30 min -24 h). Lesions were more than 30 mm in diameter and included hemorrhagic mucosal lesions, serosal congestion (Figures 2-4 ) with deteriorating vessels, losing collaterals, and branching was present in 30% or less of the initial value at the end of the experiment ( Figure 5 ). IAPDV and SMV were both congested (Figures 2 and 6 ).
Microscopically (Figure 7 ), the lesions progressed from mild villous edema with mild lymphocytic infiltrate (5 min ligation time) toward denuded villous tops with marked villous edema and submucosal capillary congestion (30 min ligation time) to the substantial subepithelial space with abundant lifting of epithelial layer from lamina propira extending down sides of villi, villous edema with capillary congestion, submucosal congestion and lymphocytic infiltrate (24 h ligation time) (Figure 7 ).
Oxidative stress and NO determination in duodenum tissue
The negative chain of events was first characterized by decreased NO levels and increased MDA levels in the duodenum tissue, followed by excessive NO release and increased MDA levels in the duodenum tissue ( Figure 8 ).
The regular course in rats with SAPDV occlusion counteracted with BPC 157 therapy
In contrast, after BPC 157 therapy (applied directly to the duodenum as a bath, or instilled into the stomach), only a few treated rats exhibited more than 10 mmdiameter mucosal lesions and serosal congestion (Figures 2-4) . Frequently, vessel presentation was markedly improved with increased interconnections, and branching increased more than 60% from the initial value ( Figure 5 ). IAPDV and SMV were both nonsacrifice, we assessed the congested hemorrhagic areas as the sum of the largest lesion diameters [21, [27] [28] [29] . As described previously [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] 15, 30] , we processed the representative tissue sections for further histological analysis.
Oxidative stress
As described before [15, 16, 31, 32] 
NO determination in duodenum tissue
In SAPDV-ligated rats, as described before [15, 16, 31, 32] , at the end of the experiment and at 5 min, 30 min and 24 L-NAME and L-arginine, given alone or together; BPC 157 treatment L-NAME and L-arginine treatment alone decreased mucosal and serosal duodenal lesions at 5 min and 30 min. Their effects were less at 24 h, but they did not further influence the loss of the collateral vessels and branching. Together, L-NAME+L-arginine antagonized each other's response at any treatment point, and thus, NO-related effects were seen. When treated with BPC 157, all SAPDV-ligated rats receiving L-NAME and/or L-arginine responded similarly to the rats treated with BPC 157 alone (Figures 2, 5 and 6).
Thus, it seems that BPC 157 rescues SAPDV failure and duodenum lesions, and its effect is related to the NO system.
DISCUSSION
We attempted to alleviate major venous obstruction and duodenal lesions in rats with stable gastric The gross appearance of the tissue was recorded using a USB microscope camera. At 1 min post-injury, medication [BPC 157, 10 μg/kg (Bμg), 10 ng/kg (Bng), L-NAME, 5 mg/kg (N), L-arginine, 100 mg/kg (A) alone and /or together (NA, BN, BA, BNA) 1 mL bath/rat] or an equal volume of a saline was applied to the duodenum of the superior anterior pancreaticoduodenal vein (SAPDV)-ligated rats (upper); alternatively, at 1 min post-injury, medication was Bμg i.g., Bng i.g., 1 mL inistillation into the stomach or an equal volume of a saline instilled into the stomach of the SAPDV-ligated rats (CON i.g.) (lower). The rats were sacrificed 5 min, 30 min or 24 h later.
a P < 0.05 vs saline. Bng: BPC 157, 10 ng/kg; Bμg: BPC 157, 10 μg/kg; N: L-NAME, 5 mg/kg; A: L-arginine, 100 mg/kg; NA: L-NAME+L-arginine; BN: BPC 157+L-NAME; BA: BPC 157+L-arginine; BNA: BPC 157+L-NAME+L-arginine; SAPDV: Superior anterior pancreaticoduodenal vein.
pentadecapeptide BPC 157 treatment and to investigate its relation to the NO system [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . In duodenal lesion development, the occlusion of the SAPDV appears as the key failure (before other vessel occlusions: i.e., left colic artery and vein ligation, and inferior caval vein ligation) [15, 16] that could never be spontaneously alleviated, even though well-placed vessels or additional therapy with NO agents [NOS-over-activation (L-arginine) and/or NOS-blockade (L-NAME)]. On the other hand, BPC 157 therapy resulted in promptly alleviated vascular presentation and then alleviated a perilous course of duodenal lesions in rats with SAPDV occlusions. We documented again "running" toward the bypassing vessel occlusion(s) [15, 16] and that BPC 157 after SAPDV occlusion quickly restores the blood supply to the ischemically injured area. BPC 157 rapidly activates collaterals much like a fundamental treatment that counteracted the injurious course (ischemic colitis [15] ; the syndrome resulting from inferior caval vein infrarenal-ligation [16] ) and this effect involves the NO system and reduction of free radical formation [15, 16] . The SAPDV-ligated rats treated with BPC 157 exhibited a complete reduction of the SAPDV-occlusion syndrome: improved vessel presentation, increased interconnections, duodenal arcade branching increased up to 60% from the initial value, and uncongested IAPDV and SMV. Thereby, BCP 157 treatment rescued the original duodenal flow through IAPDV to SMV flow and largely mitigated the duodenal lesions ( Figures  2-6 ). The results provide consistent evidence for the beneficial effects of a rapid and sustained BPC 157 μg and ng regimen.
In addition, we clarified the distinction between BPC 157 and NO-agent activity. We assumed that a prolonged occlusion would result in a more severe lesion and that a persisting and powerful defensive process would oppose these injuries and assure longlasting protection. Thus, BPC 157 therapy, along with the findings mentioned before [15, 16] , exhibited a special "bypassing" effect (through arcade vessels and/or minor and major vessels [15, 16] ) making vascular occlusion harmless and reorganizing the blood flow to counteract the duodenal lesions in rats with SAPDV-ligation. Similar to occlusion of the other vessels [15, 16] , this study indicates the early positive outcome ("bypassing" effect) of BPC 157 that may be crucial for its persisting beneficial effect, even with continuous occlusions. The effect of BPC 157 in rats with SAPDV-ligation and rats with left colic artery and vein ligations may indicate that the action of BPC 157 overlaps in the duodenum and colon [15, 16] . BPC 157 plays an important role in with respect to the "bypassing" effect that maintains duodenum and colon mucosal integrity [15, 16] and interacts with the NO system (L-NAME and L-arginine exhibited parallel effects (lesion worsening), which mitigated each other) in SAPDV, left colic artery and vein circulation, and duodenal and colon lesions [15, 16] . Together, the "bypassing" effect combined with duodenum (and colon) mucosal integrity as the revealed phenomenon could be quite complex [15, 16] as it was 
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seen with respect to the L-NAME (NOS blockade) and L-arginine (NOS over-activity) treatments, which given alone and/or together (NO-system immobilized) never exhibited the "bypassing" effect and did not provide any mucosal protection [15, 16] . However, when given together with BPC 157 (L-NAME+BC 157; L-arginine+BPC 157; L-NAME+L-arginine+BPC 157), with either SAPDVligation or left colic artery and vein ligation, the BPC 157 beneficial effect was observed, compensating either the L-NAME and L-arginine effects, while mucosal protection was seen at a higher level.
It is possible that the environment created by vessel(s) occlusion is responsible for the "bypassing" effect (SAPDV-duodenal arcade vessel interconnections-IAPDV-SMV required for adequate compensation and duodenal mucosal protection consistently obtained by BPC 157 administration) and remains outside the regular L-NAME or L-arginine influence on blood vessels but inside BPC 157 influence on NO-agent effects. L-NAME and L-arginine were given in doses necessary to instantly induce hypertension or hypotension [33] , while both effects were counteracted by BPC 157 administration [33] . Providing a complex beneficial effect, BPC 157 did not affect normal blood pressure [33] ; in addition to counteracting L-NAME induced hypertension and L-arginine induced hypotension [33] , when BPC 157 counteracted arterial [34] or venous hypertension [16] or systemic hypotension [16] , it also counteracted other disturbances, which may be related to blood pressure disturbances (i.e., potassium-overload induced arrhythmias [34] ; Virchow's triad [16] ; chronic heart failure induced by doxorubicin in hypotensive rats and mice [35] ; venous hypertension in systemically hypotensive rats with inferior caval vein occlusion [16] ). Therefore, in SAPDV-ligated rats, venous occlusion alone causes severe congestion and increased intravascular pressure [26] ; the vessels hampered with occlusions would fail to respond to either NO agent. On the other hand, this complete failure is not present in left colic artery and vein ligated rats [15] (arterial occlusion results only in reduced inflow perfusion with normal outflow [26] , arteriovenous occlusion balances inflow and outflow alteration). Thus, the arteriovenous occlusion, intravascular pressure and tone equilibrium [26] (left colic artery and vein ligated rats [15] ) still permits NO-agents activity, unlike the venous occlusion, severe congestion and increased intravascular pressure [26] (SAPDV-ligated rats). Syndrome in left colic artery and vein ligated rats [15] [the decrease (L-NAME) or increase (L-arginine)
in vessels], but without the vessel interconnection and bypassing effect, worsening the mucosal lesions (even after the initial short-lasting protective effect) accords with the more severe syndrome in SAPDV-ligated rats (vessels unresponsive to NO-agents) ( Figure 5 ). The common failure to heal SAPDV or left colic artery and vein occlusions [15] , parallelism much like in other models [15, 35, 36] , substantiates particular aspect of a NO system dual (L-NAME vs L-arginine) role (vs combination) (for review, see [1] [2] [3] [4] [5] ). Parallel L-NAME/L-arginine activity, which was noted as parallel outcomes, as a specific point (much like before [15, 35, 36] , L-NAME and L-arginine regularly attenuated or antagonized each other's responses, presenting values comparable to the control), also appeared with two pharmacologically distinct mechanisms with opposing effects on the same signaling pathway (for review, see [1] [2] [3] [4] [5] ). In SAPDV-ligated rats, this parallelism is constant with also distinctive effects, lesion attenuation (early intervals) vs lesion worsening (late interval), unless BPC 157 had been administered and the beneficial effect always attenuated the lesion [15, 35, 36] . Percent of vessels present between 5 arcade vessels on the ventral side of the duodenum 1 min following ligation before therapy (as 100%) (A); mean ± SD. The gross appearance of the tissue was recorded using a USB microscope camera. The following time points were assessed: A: After ligation and before therapy (1 min); B: 5 min after the application of medication; C: 30 min after the application of medication; D: 24 h after the application of medication. At 1 min post-injury, medication [BPC 157, 10 μg/kg (BPC 157 μg), 10 ng/kg (BPC 157 ng), L-NAME, 5 mg/kg (L-NAME), L-arginine, 100 mg/kg (L-arginine) alone and/or together (L-NAME+L-arginine, BPC 157+L-NAME,BPC 157+L-arginine, BPC 157+L-NAME+L-arginine) 1 mL bath/rat] or an equal volume of a saline was applied to the duodenum of the SAPDV-ligated rats (upper); alternatively, at 1 min post-injury, medication was BPC 157 μg, BPC 157 ng, 1 mL inistillation into the stomach or an equal volume of a saline (saline) instilled into the stomach of the superior anterior pancreaticoduodenal vein-ligated rats (lower). The rats were sacrificed 5 min, 30 min or 24 h later. For clarity, the SD is not shown on the graph; the SD was never higher than 10% of the mean. a P < 0.05 vs saline. BPC 157 μg: BPC 157, 10 μg/kg; BPC 157 ng: BPC 157, 10 ng/kg; L-NAME: L-NAME, 5 mg/kg; L-arginine: L-arginine, 100 mg/kg.
Likewise, if the NO system immobilized (mutual actions of the combined L-NAME and L-arginine), it still produces the severe pathology in the L-NAME+L-arginine animals. If this remained severe pathology is further attenuated, it means that the other system(s) (likely cholinergic and BPC 157) functioned along with. In this view, the particular role of BPC 157 reestablished effectiveness (L-NAME+L-arginine → L-NAME+L-arginine+BPC 157). It means that BPC 157 is effective (L-NAME+L-arginine+BPC 157; L-arginine+BPC 157; L-NAME+ BPC 157) with all of the NO-system presentations [inactivated (L-NAME + L-arginine); overstimulated (L-arginine); or blocked (L-NAME)] [15, 35, 36] . Thus, the three distinct NO-endpoints (NO-immobilization; -over-activity; -blockade) should be overwhelmed to achieve vessel presentation seen in rats that underwent BPC 157 treatment [15, 35, 36] . BPC 157 may consolidate the NO system to produce more effective healing (i.e., the stimulatory and inhibitory effects of the NO system promoted the interconnection of arcade vessels to bypass major obstructions) (a result not observed with L-NAME or L-arginine treatment) [15] . This special BPC 157 role seems to be supported by the NO and MDA values seen in the duodenal tissues. The beneficial effects promptly counteract the full negative syndrome. Otherwise, after SAPDVligation, sudden decrease of blood supply appears. NOlevels decrease in the duodenum tissue. Heavy loss of endothelial cells occurs immediately from the vascular wall [37] . A lower eNOS production ability [37] , oxidative stress appears as a result of the lysis of endothelial cells [38, 39] ; and excessive NO release generated by the inducible isozyme damaging the vascular wall and other tissues cells, especially in combination with reactive oxygen intermediates, and failing endothelial production [32, 40, 41] . The positive chain of events includes a BPC 157 treatment restored endothelial integrity and reversed most of the oxidative damage [15, 16, 31, 32] while interacting with the NO system [1] [2] [3] [4] [5] . The positive endothelium syndrome (i.e., increased duodenal NOvalues, but normal MDA-values, indicative of adequate eNOS system function [1] [2] [3] [4] [5] ) appears with general significance, and thereby, restored endothelial integrity and reversed most of the oxidative damage. With BPC 157, this recovery appears even during reperfusion (occurring while vessel occlusion is still present) much like during exaggerated reperfusion (occurring when vessel occlusion is removed) [15] . There is evidence that BPC 157 also affects several other molecular pathways [16, [42] [43] [44] [45] [46] [47] , and thereby, the rapid recruitment of existing blood vessels following ongoing harmful events instead otherwise poor response to increased demands. Combined, these findings may substantiate the effects of which were seen at the later time point. In addition, this may accentuate the original cytoprotection understanding (endothelium maintenance → epithelium maintenance) [17] [18] [19] [20] [21] to the complexity of reestablishing original flow by bypassing occlusion [15, 16] . And thereby, we documented recovery of SAPDV-occlusion by AIPDV → SMV, or ICV-occlusion by LOV and other veins [16] , or even two obstructions, the proximal and distal ligations in the left colic artery and vein through arcades within the ligations in rats with colitis [15] . Furthermore, its subsequent strong angiogenic effect and its healing effects [9, [43] [44] [45] [46] [47] [48] [49] may be consequence of the specific activation of the collateral circulation that can circumvent obstructions and reestablish the continuity of blood flow [15, 16] . And thereby, its angiogenic effect and its healing effects [9, [43] [44] [45] [46] [47] [48] [49] may overcome those of standard anti-ulcer agents [48] . Also, these effects are likely to be further extended. BPC 157 accelerates the blood flow recovery and vessel number in rats with hindlimb ischemia [43] . BPC 157 upregulates VEGFR2 expression in rats with hindlimb ischemia and endothelial cell cultures and promotes VEGFR2 internalization in association with VEGFR2-Akt-eNOS activation [43] . As mentioned, shared limitation of activity [17] [18] [19] [20] [21] 50] , only prophylactic effectiveness of standard cytoprotective agents, is avoided. With both prophylactic and therapeutic abilities [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] , native and stable in human gastric juice BPC 157 as a novel mediator of Robert's cytoprotection [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] maintains gastrointestinal mucosal integrity [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . In addition, the comparative effectiveness of BPC 157 when instilled into the stomach supports this contention of a prototype of a more effective class of cytoprotective agents.
In conclusion, this study provides evidence for a "bypassing" effect combined with mucosal integrity (i.e., duodenum and colon) or major vessel obstruction made harmless [15, 16] as observed after BPC 157 treatment, which can be regarded as an implementation of the original cytoprotection concept in vascular occlusion therapy.
ARTICLE HIGHLIGHTS
Research background
The research background was our recent claim that treatment with the prototype cytoprotective agent, stable gastric pentadecapeptide BPC 157, induced bypassing of occlusions in rats that underwent vessel occlusions through the rapid presentation of collaterals. In this study, we focused on the resolving of the duodenal lesions induced by major venous occlusions. These lesions can be counteracted by BPC 157 regardless of the involvement of the nitric oxide (NO) system while recruitment of blood vessels to bypass obstruction may occur quickly.
Research motivation
Research motivation was to resolve the major venous occlusions and duodenal lesions in the rat with the use of the stable gastric pentadecapeptide BPC 157 and/or NO-agents, L-NAME (NOS-blocker) and L-arginine (NOS-substrate). BPC 157 is a prototype cytoprotective agent used in ulcerative colitis and multiple sclerosis trials (LD1 not achieved) and is known to counteract duodenal lesions. Rat duodenal lesion research is mostly based on cysteamine and acetic acid models. Investigations are sparse on the impact of major venous obstruction and whether recruitment of blood vessels to bypass obstruction may occur quickly, and if so, whether it may be facilitated by a suitable therapy. 
ARTICLE HIGHLIGHTS
Research objectives
Research objectives were the occluded superior anterior pancreaticoduodenal vein (SAPDV) and duodenal lesions (congestion) and the recovering effect (rapidly activated collaterals bypassing vascular occlusion, absent lesions), the therapy effect of stable gastric pentadecapeptide BPC 157 vs harmful effect of NO-agents [L-NAME (NO-system-blockade), L-arginine (NO-system overstimulation); L-NAME+L-arginine (NO-system immobilization)]. We recorded the vessel presentation (filled/appearance or emptied/disappearance) between the 5 arcade vessels arising from the SAPDV on the ventral duodenum side, the inferior anterior pancreaticoduodenal vein (IAPDV), superior mesenteric vein (SMV) as bypassing vascular pathway to document the duodenal lesions presentation. In duodenum, BPC 157 normalizes NO-levels and counteracts increased oxidative stress [malondialdehyde (MDA)]-levels.
Research methods
For research methods, we used rats with the occluded SAPDV and duodenal lesions (congestion) to reveal the recovering effect (rapidly activated collaterals bypassing vascular occlusion, absent lesions), at 5 min, 30 min and 24 h ligation time. Therapy effect of the stable gastric pentadecapeptide BPC 157 was achieved with two regimens (10 μg, 10 ng/kg per 1 mL bath/rat or 10 μg/kg instilled into the rat stomach), at 1 min ligation-time. Harmful effect of NO-agents [L-NAME (NO-system-blockade), L-arginine (NO-system overstimulation); L-NAME+L-arginine (NO-system immobilization)] goes with L-NAME 5 mg/kg per 1 mL bath/rat; L-arginine 100 mg/kg per 1 mL bath/rat, alone and/or together. Considering the point immediately before therapy (as 100%), we scored the vessel presentation [recorded filled/appearance or emptied/disappearance (camera attached to a USB microscope)] between the 5 arcade vessels arising from the SAPDV on the ventral duodenum side, the IAPDV, SMV as bypassing vascular pathway. Upon the duodenum opening and after sacrifice, we assessed the congested hemorrhagic areas as the sum of the largest lesion diameters. In the collected duodenal tissue samples, we assessed NO-levels (Griess reaction) and oxidative stress [by quantifying thiobarbituric acid-reactive species (TBARS) as MDA equivalents].
Research results
For research results, we attempted to alleviate major venous obstruction and duodenal lesions in rats with stable gastric pentadecapeptide BPC 157 treatment and to investigate its relation to the NO system. In duodenal lesion development, the occlusion of the SAPDV appears as the key failure (before other vessel occlusions: i.e., left colic artery and vein ligation, and inferior caval vein ligation) that could never be spontaneously alleviated, even though wellplaced vessels or additional therapy with NO agents [NOS-over-activation (L-arginine) and/or NOS-blockade (L-NAME)]. On the other hand, BPC 157 therapy resulted in promptly alleviated vascular presentation and then alleviated a perilous course of duodenal lesions in rats with SAPDV occlusions. We documented again "running" toward the bypassing vessel occlusion(s) and that BPC 157 after SAPDV occlusion quickly restores the blood supply to the ischemically injured area. BPC 157 rapidly activates collaterals much like a fundamental treatment that and counteracted the injurious course (ischemic colitis; the syndrome resulting from inferior caval vein infrarenal-ligation) and this effect involves the NO system and reduction of free radical formation.
Research conclusions
The new phenomena that were found through experiments in this study of the duodenal lesions with an obstructed major vein (SAPDV) offered is the early positive outcome ("bypassing" effect) of BPC 157. The hypotheses that were confirmed through experiments in this study are related to the cytoprotective agents, to the effects originally noted in the stomach, which is the rapid endothelial protection. Using BPC 157 as a prototype cytoprotective agent, these mechanisms can prevent and resolve adjacent ischemic mucosal lesions providing activation of the collateral circulation. This activation is specific and can circumvent obstructions. That effect may be crucial for its persisting beneficial effect, even with continuous occlusions. The effect of BPC 157 in rats with SAPDV-ligation and previously, in rats with left colic artery and vein ligations may indicate that the action of BPC 157 overlaps in the duodenum and colon. BPC 157 plays an important role in with respect to the "bypassing" effect that maintains duodenum and colon mucosal integrity and interacts with the NO system [L-NAME and L-arginine exhibited parallel effects (lesion worsening), which mitigated each other] in SAPDV, left colic artery and vein circulation, and duodenal and colon lesions. Thus, these findings can be regarded as an implementation of the original cytoprotection concept in vascular occlusion therapy.
Research perspectives
For research perspectives, we attempted to alleviate major venous obstruction and duodenal lesions in rats with stable gastric pentadecapeptide BPC 157 treatment and to investigate its relation to the NO system. In duodenal lesion development, the SAPDV occlusion appears as the key failure that could never be spontaneously alleviated, even though well-placed vessels or additional therapy with NO agents [NOS-overactivation (L-arginine) and/or NOS-blockade (L-NAME)]. Finally, BPC 157 therapy results in "bypassing" effect combined with mucosal integrity, or major vessel obstruction made harmless. These BPC 157 effects can be an implementation of the original cytoprotection concept in vascular occlusion therapy. MDA (nmol/mg protein), means ± SD
